Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 21, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details a specific transaction on October 20, 2005, where Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 387 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on October 21, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held in the GSK Trust in the same manner as other employees. The notification complies with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of shares held by the GSK Trust and the impact of the 387-share transfer on overall director holdings.
- Confirm the specific terms of the SmithKline Beecham Employee Share Option Plan 1991 regarding vesting and exercise conditions.
- Review subsequent filings to determine if this transaction was part of a larger pattern of employee share plan activity.